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This document has been prepared for the Advance Market Commitment (AMC) for 
pneumococcal vaccines.  The AMC is a financial commitment to subsidize the future purchase, 
up to a pre-agreed price for a vaccine not yet available, if it is requested by a GAVI-eligible 
country.  The pneumococcal vaccine has been selected to pilot this new financing instrument.  
As part of the AMC process, specifications for eligible products need to be defined in advance.  
These product specifications are called the target product profile (TPP).  In accordance with the 
relevant AMC legal documents, the characteristics are set at the beginning of the AMC process 
and can subsequently only be modified by the independent assessment committee (IAC) to 
render the product requirements less stringent.  The TPP defines essential criteria that relate to 
the public health impact and suitability of the product, covering measures of vaccine efficacy, 
safety, dose-scheduling, presentation and packaging.  The suitability for use in GAVI-eligible 
countries is the overall guiding principle.  At the same time the criteria should help to stimulate 
a competitive vaccine supply environment, by providing incentives to a large number of vaccine 
developers.  Therefore, essential vaccine attributes need to be demanding, yet realistic, in 
relation to the innovation that can be achieved over the duration of the pneumococcal AMC.  
All attributes must be unequivocal and measurable by vaccine developers. 
The target product profile should be read together with WHO requirements for product 
prequalification, and all the related WHO technical documents and guidelines applied in this 
process.  Wherever applicable, the TPP refers to these documents, but sets additional criteria in 
accordance with the expected use of the pneumococcal vaccines in GAVI-eligible countries.  In 
relation to some TPP attributes, scientific advances may lead to refined criteria over the coming 
years.  In these cases, and as indicated in the TPP, the relevant future WHO guidelines should 
apply. 
While the most advanced pneumococcal candidates vaccines are conjugate vaccines containing 
capsular polysaccharides, other vaccines based on common proteins may reach the market 
during the AMC period.  Most attributes set in the TPP are not linked to a specific vaccine 
technology, but for a protein based vaccine some attributes will require adaptation.  The public 
health benefit (i.e. prevention of pneumococcal disease) of these novel vaccines should be 
equivalent or better than that defined for conjugated vaccines.  
The essential (Minimally Acceptable Profile) product criteria are included in the TPP Master 
Table and both essential and desirable attributes for new pneumococcal vaccines are described 
in this document.  While the table sets the minimum requirements for eligibility for AMC 
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manufacturers to develop pneumococcal vaccines with improved performance in GAVI-eligible 
countries. 
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A.  S. pneumoniae and pneumococcal disease 
 
S. pneumoniae is a major cause of both mild and severe infections worldwide.  The primary 
clinical syndromes associated with pneumococcal infections are pneumonia, meningitis, 
bloodstream infections and acute otitis media, with pneumonia being the most important of 
these in terms of total morbidity and mortality.  Of the estimated 10 million deaths worldwide 
amongst children less than 5 years of age each year, WHO estimates that more than 700,000 are 
caused by pneumococcal infections.  Disease rates are highest in children <5 years of age, are 
low in older children and healthy young adults, and increase again in the elderly (1;2).   
Pneumococcal disease is endemic worldwide, but the observed incidence of infection varies 
geographically, not only because of true differences in disease risk but also because of variation 
in the use of diagnostic tests.  Rates of disease, deaths, and complications are higher in 
developing countries than in industrialized settings, with the majority of deaths occurring in 
Africa and Asia.  In the US, which has among the highest reported invasive disease rates for 
industrialized countries, annual invasive disease incidence was 96/100,000 children <5 years 
before the pneumococcal conjugate vaccine was introduced (3).  A recent study in Kenya 
estimated an incidence of presentation to hospital with pneumococcal bacteraemia of 
597/100,000 children <5 years of age per year (4).  Case fatality can be high for invasive 
pneumococcal infections, ranging up to 20% for sepsis and 50% for meningitis in developing 
countries.  Among meningitis survivors, long-term neurologic sequelae such as hearing loss, 
mental retardation, motor abnormalities and seizures can occur in up to 58% of cases, as seen in 
The Gambia (5). 
Major risk factors for disease include young age (particularly age <2), underlying 
immunodeficiency (such as HIV infection or AIDS), certain other chronic illnesses, day care 
attendance and exposure to household and tobacco smoke; breastfeeding has been shown to be 
protective.  Invasive disease rates vary, and are higher among indigenous populations of 
Australia and New Zealand and among the Black, Alaska Native and some American Indian 
populations in the US relative to the general population (6-8). 
Ninety distinct serotypes of S. pneumoniae have been identified based on structural differences 
in the polysaccharide capsule, but according to previous analyses approximately 10 or 11 
serotypes account for over 70% of invasive paediatric infections in all regions of the world (9). 
The distribution of serotypes causing disease varies by age, disease syndrome, disease severity, 
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been reported from the African meningitis belt (10;11).  Pneumococci that are resistant to 
penicillin, erythromycin, co-trimoxazole or multiple drugs are common in many regions (12). 
 
B.  Pneumococcal carriage 
 
Pneumococcal carriage isolates are the source of invasive strains in an individual. The 
epidemiology and characteristics of carried isolates are thus directly relevant to disease 
epidemiology. In a study of the natural history of pneumococcal infection in US children 
followed from birth, nearly all (79 of 82) were found to carry one or more pneumococcal 
serotype by their second birthday (13).  Children acquired their first type by a mean age of 6 
months, and duration of carriage was found to decrease with successive strains carried.  For 24 
infants who developed pneumococcal disease (28 episodes of otitis media, two of bacteraemia, 
and one of meningitis), the illness usually occurred within 1 month of acquiring a new serotype, 
and the carriage serotype usually matched the serotype causing disease.  
Pneumococcal carriage is more common and prolonged among children than among adults   
(14;15).  Carriage has also been noted to be significantly more common and occurs earlier 
among children in developing countries than in industrialized settings.  While most information 
on carriage is from developed countries, some studies have been conducted describing the 
epidemiology of NP carriage in developing world settings.  As an example, in South Africa, the 
prevalence of pneumococcal carriage was 30% among children sampled at age 6
 weeks, 44% at 
10 weeks, 51% at 14
  weeks and 61% at age 9 months (16).  There are other countries or 
subpopulations within countries where the prevalence of pneumococcal carriage in the 
nasopharynx occurs even earlier than this and where the rates of colonization are even higher.  
 
 C.  Current conjugate vaccines  
 
Conjugate vaccines represent a technical advance over pure polysaccharide vaccines as they 
induce antibodies in young children under the age of 2 years.  The inability of pure 
pneumococcal polysaccharide vaccines to induce a protective immune response for important 
serotypes in young children precludes their consideration for infant immunization.  A 7-valent 
pneumococcal conjugate vaccine (PCV7) is the only conjugate formulation that is currently 
licensed and it has been recommended for use in developing countries with high disease burden 
by WHO’s Strategic Advisory Group of Experts (SAGE)(17).  A 10-valent (PCV10) and a 13-
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the next few years.  Additional phase III trials have been performed using 9-valent (PCV9) and 
11-valent (PCV11) vaccines that are not expected to reach market.  Twenty other pneumococcal 
conjugate vaccines are in early stages of development (18). 
 
Table 1: Pneumococcal conjugate vaccines: licensed or in late stage of development 
Manufacturer Serotype 
composition 
Carrier Current 
status 
Use Worldwide 
Wyeth (Prevnar/ 
Prevenar) 
7 serotypes  
4, 6B, 9V, 14, 
18C, 19F, 23F 
CRM197 licensed  In use. USA since 2000, 
widespread European 
introduction from 2006 
GSKBio 10  serotypes 
7-valent + 1, 5, 
7F 
Protein 
D 
phase III   
Wyeth 13  serotypes 
7-valent + 1, 3, 
5, 6A, 7F, 19A 
CRM197 phase III   
(i) Pneumococcal conjugate vaccine efficacy trials 
The Northern California Kaiser Permanente (NCKP) trial assessed PCV7 impact on pneumonia 
and invasive disease.  Vaccination reduced episodes of pneumonia confirmed by radiograph by 
20% (19).  Vaccine effect on radiologically confirmed pneumonia was greater in children <2 
years (23% reduction) than among children ≥2 years (9% reduction).  A later analysis of these 
data using WHO radiograph protocols reported that the efficacy against pneumonia was 25.5% 
in an intention to treat analysis, and 30% per protocol (20).  Efficacy against invasive disease 
caused by vaccine serotypes was 97% (21).  In a community randomized trial in the US, PCV7 
was found to be effective against invasive disease among Navajo and Apache children <2 years 
of age, reducing episodes caused by vaccine serotypes by 83% (15).  
Two trials of PCV9 have been completed in developing countries; the first found that 
vaccination prevented invasive disease in both HIV-positive and HIV-negative infants in South 
Africa, although point estimates of efficacy were higher in HIV-negative children, 85% vs. 65% 
(22).  Vaccination significantly reduced radiologically-confirmed pneumonia in children who 
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reduced radiologically-confirmed pneumonia by 37% and invasive disease caused by vaccine 
serotypes by 77% (23).  The most striking findings in this second trial were that vaccination 
reduced hospital admissions and deaths from any cause by 15% and 16%, respectively.  A third 
study conducted in Bohol in the Philippines has been completed but results have only been 
presented orally in abstract form [12
th International Congress on Infectious Diseases, Lisbon 
2006].  Infants received 3 doses of an experimental 11-valent bi-carrier vaccine (sanofipasteur) 
before the age of 6 months: the primary endpoint in the study was the first episode of 
radiologically-confirmed pneumonia.  The vaccine prevented approximately one quarter of all 
pneumonia in children under the age of 2 years.  
Efficacy studies in the US, Israel and Europe have evaluated the effects of conjugate vaccines 
on otitis media.  In a large randomized, double-blinded clinical trial among NCKP members, 
infants receiving PCV7 (at 2, 4, 6 and 12-15 months) had 7% fewer episodes of otitis media, 9% 
fewer infants with frequent otitis media, and 20% fewer children requiring ventilatory tube 
placement compared to controls (21).  In a trial in Finland, infants receiving PCV7 had 6% 
fewer episodes of otitis media (24), with 57% fewer episodes of otitis media caused by vaccine 
serotypes.  Notably, children in the PCV7 vaccine group had 33% more episodes of otitis media 
caused by non-vaccine serotypes.  In Israel, PCV9 vaccination reduced episodes of otitis media 
in day-care attendees aged 12-35 months, but the change was not statistically significant (17% 
fewer episodes, 95% CI –2 to 22%) (25).  Significant reductions were seen for upper and lower 
respiratory tract infections and days of antibiotic use.  However, a study in the Netherlands, 
where PCV7 was given in combination with 23-valent pneumococcal polysaccharide vaccine 
(PPV23) to children aged 1 to 7 years with a history of recurrent otitis media, reported no 
significant benefit for reducing ear infections (26).  Another study conducted in the Czech 
Republic and Slovakia used an 11-valent vaccine containing the 9-valent serotypes + serotypes 
3 and 7F, each conjugated to protein D of H. influenzae (27).  The vaccine was shown to 
provide an efficacy of 52.6% against vaccine serotypes when assessed against the endpoint of 
acute otitis media diagnosed on referral to an ENT specialist.  Overall effect against any acute 
otitis media was 33.6%, including protection afforded by protein D against H. influenzae 
infection.  
(ii) Vaccine effectiveness following introduction into national immunization 
campaigns (direct and indirect effects) 
The US was the first country to introduce pneumococcal conjugate vaccine, adding it to the 
routine infant schedule (at 2, 4, 6 and 12-15 months) in 2000.  Intermittent supply problems 
from 2001 through 2004 may have slowed introduction elsewhere and reduced vaccine coverage 
among infants in the US.  As of early 2007, 16 countries are routinely using PCV7 for all 
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Mexico, Norway, Qatar, Switzerland, The Netherlands, UK, US).  Most countries have 
implemented a 2-dose or 3-dose schedule in early infancy with an additional dose between the 
ages of 11 and 18 months.  In addition, 30 GAVI-eligible countries have expressed interest in 
introducing PCV7. 
Routine use of PCV7 in the US has rapidly reduced rates of invasive pneumococcal disease in 
children.  The impact of the vaccine was noted within 1 year of introduction.  According to 
CDC’s Active Bacterial Core Surveillance (ABCs) the incidence of invasive pneumococcal 
disease among children <5 years dropped 75% from 97 cases per 100,000 population during 
1998 and 1999 to 24 cases per 100,000 population in 2005; disease caused by vaccine-type 
strains fell 94% from 80 cases per 100,000 population to 4.6 (2;3).  A multi-centre study of 
hospitalized patients found that 77% fewer cases in children <2 years were caused by vaccine 
serotypes in 2002 compared to the average number of cases during 1994 to 2000 (28).   
Surveillance programmes evaluating PCV7 in single geographic areas in the United States have 
generally reported findings similar to the multi-site studies (29-32), with the exception of Utah 
(33), where an increase in disease caused by non-vaccine serotypes reduced the overall effect on 
disease burden.  PCV7 use also appears to be reducing non-invasive pneumococcal infections, 
including otitis media and pneumonia (34-37).  In a recent study using the Nationwide Inpatient 
Sample, the largest available inpatient database in the U.S., an interrupted time-series analysis 
found reductions in hospitalizations coded as all-cause and pneumococcal pneumonia 
comparing 1997-1999 (pre-PCV7 years) to 2001-2004 (post-PCV7 years) (35).  In addition, 
PCV7 reduced differences in the risk of invasive vaccine-type pneumococcal disease between 
racial and ethnic groups (7;38).  Published surveillance data on vaccine impact from outside the 
US are currently limited.  Data from the Calgary area in Canada showed a 93% reduction in 
vaccine-type invasive disease in children <2 years of age (39).  In Australia, early data 
suggested a reduction in cases of PCV7-serotype disease in indigenous children <2 years of age 
(8).  
The direct effectiveness of PCV7 against invasive disease has been formally evaluated.  Two 
surveillance programmes—the U.S. Pediatric Multicenter Pneumococcal Surveillance Group 
and the Massachusetts Department of Public Health— combined their data and used a case-only 
method to estimate the effectiveness of abbreviated or delayed dosing regimens against invasive 
pneumococcal disease (40).  In children not at high risk for invasive disease, the effectiveness of 
the full 4-dose schedule vaccine against vaccine serotypes was estimated to be 91%.   
Effectiveness was somewhat higher when measured in a large case-control study that used cases 
of invasive disease identified through US CDC’s ABC multi-site surveillance programme and 
age-matched controls.  This study found that 1 or more doses of PCV7 was 96% effective 
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conditions and 76% effective overall against disease caused by strains resistant to penicillin 
(41).  Vaccination was shown to be significantly protective against all 7 individual vaccine 
serotypes and vaccine-related serotype 6A, but not against vaccine-related serotype 19A.  A 
case-control study from Spain also reported high effectiveness (88%) against invasive disease 
caused by vaccine serotypes.  The study found a higher likelihood of nonvaccine type disease 
among vaccinated children (matched odds ratio 6.2, 95% CI 1.6- 23.3), however, than among 
controls.  Methods for case identification and verification of vaccination histories differed from 
those used in other studies and the study occurred in a setting of low vaccine coverage (27% 
among controls), which may in part explain the findings (42).  
In the US, invasive disease in adults 65 years and older has dropped by about one-third since 
introduction of pneumococcal conjugate vaccine for children, due to an approximately 80% 
reduction in disease caused by PCV7 serotypes between 1999 and 2005 (CDC unpublished 
data) demonstrating the powerful indirect effect of the vaccines.  A drop of similar magnitude 
was seen in hospitalizations for pneumococcal bacteraemia in older adults (43).  In Calgary, 
Canada, however, early surveillance data did not find an overall decrease in adult disease (39).  
Following PCV7 introduction, invasive disease caused by PCV7 serotypes fell by about half 
among newborns and infants too young to have been vaccinated (44).  Among adults, indirect 
benefits were as strong among African-American, who are at higher risk for invasive disease, as 
were seen among persons of white race (38).  Between pre-vaccine years (1998 and 1999) and 
2003, an overall reduction of 19% in invasive disease rates was noted among adults 18-64 years 
of age with HIV or AIDS, a group with disease rates up to 100 times that of healthy adults the 
same age (45).  In contrast to the findings for invasive disease, rates of pneumonia 
hospitalizations among older adults have not dropped significantly following PCV7 introduction 
(35). 
(iii) Serotype replacement:  In most but not all pneumococcal carriage studies, carriage of 
non-vaccine type strains increased among children receiving conjugate vaccine. Despite the 
reduction in carriage of vaccine serotypes the overall prevalence of pneumococcal carriage was 
not different in vaccinated and unvaccinated children (15).  The implications of this replacement 
colonization in terms of disease are not yet clearly understood, although replacement disease is 
not anticipated to result in increases in the overall burden of pneumococcal disease (18).   
Replacement disease was not observed in the invasive disease efficacy trials, but in the Finnish 
Otitis Media trial, children in the pneumococcal vaccine group had 33% more episodes of otitis 
media caused by serotypes not in the vaccine or related to vaccine types (24).  Measurement of 
serotype replacement after vaccine introduction is complicated by the natural variation in 
serotype distribution over time.  In the US, a relatively small but statistically significant increase 
  Page  12  18/12/2008 was seen in invasive disease caused by non-vaccine-type strains, in particular serotype 19A after 
PCV7 introduction (46).  Surveillance in Utah, where the overall reduction in disease was only 
27%, showed that a decrease in vaccine-type disease was accompanied by an increase in non-
vaccine type disease (33).  Recent data also indicate that an increase in invasive disease caused 
by non-vaccine-type pneumococci has eroded some benefits of PCV7 among Alaska Natives 
(47).  Overall, serotype replacement has so far had only minimal impact on vaccine 
effectiveness, and the measured replacements may in part be due to secular trends or antibiotic 
use patterns.  Vaccine introduction should be accompanied with disease surveillance to monitor 
the occurrence of replacement disease. 
 
C.  Cost-effectiveness 
Most published studies of the cost-effectiveness of pneumococcal vaccine have been done in the 
US or in Western European countries.  Recently, however, Sinha et al (2007) carried out an 
analysis of the available 7-valent pneumococcal conjugate vaccine for the 72 countries that in 
2005 were eligible for financial support from GAVI  (48).  The analysis found that at a cost of 
$5 per dose, the programme would cost around $100 per DALY, ranging from $56 in 
Azerbaijan up to $14800 in Cuba.  If each country’s per capita gross domestic product were 
used as the benchmark for a ‘highly cost-effective and affordable’ intervention, the vaccine 
would qualify in 68 of the 72 countries.  Assuming a 3 x GDP as benchmark it would be cost-
effective in a further 3 countries. 
The most important determinants of cost-effectiveness were vaccine cost and the vaccine’s 
impact on mortality.  Costs of $1 to $10 per dose were used in different scenarios.  At $10 per 
dose the cost per DALY increased to around $200 on average.  If one assumes a high price ($7 
per dose) and a lower impact on all-cause mortality (3%, rather than the 7% central estimate), 
the overall cost/DALY rises to $500.  
The analysis was intended to be conservative, meaning that the analysis excluded factors that 
would have improved the cost-effectiveness of the vaccine.  The only benefits of vaccination 
accounted for were prevention of deaths among children aged 3 to 29 months.  Benefits from 
prevention of deaths after 29 months of age and of non-fatal morbidity, including avoidance of 
the associated health care costs of treatment, were excluded.  A secondary analysis 
incorporating non-fatal disease reduced the cost to $80 per DALY averted.  Although benefits 
of this kind were disproportionately found in countries with well-developed health care 
infrastructures, the potential to prevent large numbers of hospitalizations could prove important 
in countries with low mortality rates.  Benefits to unvaccinated children and adults through herd 
immunity were also excluded.  In US-based analyzes, ‘external’ benefits through herd immunity 
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chose not to extrapolate the US results to the GAVI-eligible countries.  On the other hand two 
factors were excluded that could have an adverse effect on cost-effectiveness: the occurrence of 
serotype replacement and delays in children receiving vaccine doses.  
In summary, the limited evidence available suggests that pneumococcal conjugate vaccines that 
reduce mortality by 7% would be highly cost effective in the great majority of GAVI-eligible 
countries if the price is around $5 per dose or less.  Vaccine formulations that contain serotypes 
that prevent a lower proportion of disease than was assumed in the study by Sinha et al may 
require additional cost-effectiveness analyses.  
 
E. Protein based vaccines 
The pneumococcal AMC does not stipulate the type of pneumococcal vaccine eligible, therefore 
protein-based pneumococcal vaccines should they become available during the course of the 
AMC, are potentially eligible for AMC funds.  Many of the requirements outlined in this TPP 
are theoretically applicable to protein vaccines.  However, protein vaccines are still in pre-
clinical or early clinical development and their pathways to licensure are not yet defined.  The 
most important open question includes the demonstration of vaccine efficacy in direct 
comparison to licensed conjugated vaccines.  To date, only one protein vaccine, which 
contained PspA and PsaA has been assessed in phase 1 studies in adults.  As stated in the scope 
of the document, eligibility criteria for these vaccines will need to be developed as vaccine 
candidates’ progress. 
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to the Target Product Profile  
 
A.  Vaccine serotypes 
 
The vaccine’s public health impact in different geographic settings will depend upon the match 
between vaccine serotypes and the pneumococcal serotypes that account for paediatric 
pneumococcal disease locally.  Hence, AMC eligible vaccines must include at least a minimum 
set of strains to assure that an adequate public health impact is achieved in regions where the 
vaccines will be used.  The 2008 Pneumococcal Global Serotype Project (GSP) undertook a 
systematic literature review and meta-analysis of published and unpublished studies of invasive 
pneumococcal disease isolates from around the world (http://www.preventpneumo.org/pdf/GSP 
Version 2 Summary for IAC 2008Dec.pdf).   The aim of the GSP was to establish the serotype 
distribution of disease causing strains among children < 5 years of age globally and regionally.  
The GSP analysis includes 169 studies from 70 countries and data on >60,000 isolates. The 
analysis is reasonably robust at a global and regional level but data paucity makes sub-regional 
analyses less reliable.  
The GSP analysis has several key findings. Serotype 14 is the most common serotype in all 
regions of the world among children< 5 years.  Serotypes 1 and 5 are among the top 6 ranked 
serotypes occurring among children < 5 years in regions with the highest pneumococcal disease 
burden (Africa, Asia, and Latin America, and the Caribbean) and among the top 3 ranked 
serotypes occurring in GAVI-eligible countries as a whole.  A limited set of seven serotypes (1, 
5, 6A, 6B, 14, 19F, 23F) are common and important in all regions with a substantial number of 
GAVI eligible countries. Together, these 7 serotypes account for ~58%-66% of all invasive 
pneumococcal disease in each region. Vaccines with fewer than 10 serotypes can provide broad 
protection. With as few as 6-7 serotypes (including serotypes 1, 5, and 14, and assuming 6A/B 
cross-protection), it should be possible to develop pneumococcal conjugate vaccines that 
include serotypes causing at least 60% of all invasive pneumococcal disease in each region..  
Although a 60% coverage level may be considered moderate, vaccines that include serotypes 
with this level of coverage would be expected to have a considerable public health impact and 
be favourably assessed by cost effectiveness analysis.  
 
Based on these findings, vaccines will be assessed for AMC eligibility based on two 
requirements:  (1) they must include serotypes 1, 5 and 14, and (2) the serotypes included in the 
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level. In calculating the cumulative proportion of disease covered by a putative product, 
manufacturers may wish to include serotypes that are related to those in the vaccine, the so-
called cross-reactive types.  In order to include the proportion of disease accounted for by cross-
reaction from a type included in the vaccine, manufacturers must provide evidence that the 
product is highly likely to provide protection against disease from the cross-reactive type of 
interest. 
Serotypes 1, 5 were selected as essential serotypes because these are among the most common 
types in regions particularly relevant to GAVI and are of epidemic and endemic disease 
importance especially in Asia and Africa, the two regions with the greatest pneumococcal 
disease burden among children.  Serotype 14 was also included as an essential serotype because 
it is the most common isolate among children below 5 years of age in all regions. The 
stipulation of these three serotypes is not intended to diminish the importance of other 
serotypes.  Manufacturers are strongly encouraged to develop formulations which take 
into consideration the major disease causing serotypes in regions and globally.  They are 
also encouraged to select formulations which address the importance of antimicrobial 
resistance and the potential for serotype replacement disease [For estimations on serotype 
specific prevalence in different geographic regions of the world refer to the 2008 GSP report,  
available at: http://www.preventpneumo.org/pdf/GSP Version 2 Summary for IAC 
2008Dec.pdf]. 
The choice of 60% coverage was selected on the basis of several principles, balancing the 
imperative for a significant public health benefit with the likelihood that manufacturers will be 
motivated and successful in developing pneumococcal vaccines for the GAVI market.  
First, the 60% coverage accounts for the smallest number of serotypes responsible for the 
greatest amount of invasive disease.  In regions with GAVI-eligible countries (i.e. all regions 
except North America), the incremental coverage by serotypes beyond 60% becomes smaller 
and smaller.  For example, 60% coverage requires 4-7 serotypes for each region (assuming 
6A/6B cross-protection), while 80% coverage (i.e. an additional 20% coverage) requires 2-8 
additional serotypes in each region except Asia which requires an additional 14 serotypes.  
Second, a single formulation covering at least 60% of disease in every region is possible with 
only 6-7 serotypes, again assuming 6A/6B cross-protection.  Limiting the number of serotypes 
decreases the complexity of the vaccine and thus increases the number of manufacturers likely 
to successfully make pneumococcal vaccines.  
Third, when applied to the absolute burden of pneumococcal disease in children, 60% coverage 
still represents a major public health impact thereby assuring that all AMC eligible vaccines 
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complexity in the production for relatively smaller increases in health impact.  
Furthermore, the proposed 60% level is consistent with the level of protection on which a cost-
effectiveness analysis of pneumococcal conjugate vaccine in GAVI-eligible countries was based 
(48).  This cost-effectiveness analysis, which contributed to decision-making for introduction of 
these vaccines, was based on the mortality impact from The Gambia pneumococcal vaccine trial 
(23).  In that trial, the vaccine prevented 50% of invasive pneumococcal disease (IPD) - that is, 
IPD due to all serotypes.  With this 50% reduction in pneumococcal disease, there was also a 
16% reduction in all-cause child mortality among vaccine recipients – a prevention of 7.4 deaths 
for every 1000 vaccinated children.   
The model estimated the impact on mortality in other countries by indexing The Gambia trial 
mortality reduction on the relative under 5 mortality rate in The Gambia compared with that of 
other countries.  For example, the impact of PCV on mortality in a country with an under 5 
mortality rate half of that seen in The Gambia was assumed to be 8%, or half of 16%. 
How does the 60% serotype requirement link with The Gambia trial results and the cost-
effectiveness analysis?  The 50% impact on all-serotype invasive pneumococcal disease is, by 
definition, the product of the proportion of the serotypes covered by the vaccine and the 
vaccine’s efficacy against serotypes in the vaccine.  A recent Cochrane meta-analysis of all 
PCV efficacy trials around the world estimated efficacy against vaccine-serotype invasive 
disease to be 88% (49).  Assuming 88% efficacy against vaccine serotype IPD, a 50% reduction 
in all invasive pneumococcal disease requires a vaccine with 57% serotype coverage.   
Therefore, 60% coverage should assure that vaccines provide a health impact similar to or 
higher than that used in the cost-effectiveness analyses for GAVI-eligible countries reported by 
Sinha et al. 
AMC eligibility should be based on regional data as defined in the GSP 2008 report, even if 
subregional and country level data are available.  If a country is in a region where a vaccine 
formulation was found to meet the two required AMC eligibility criteria based on the GSP 2008 
report, then the country may request that vaccine formulation under the AMC, notwithstanding 
reliable sub-regional or country level data to the contrary.  However, in choosing between 
different AMC-eligible vaccines it is likely that countries will be influenced by their expected 
impacts on disease.  Updates to the Pneumococcal GSP will be carried out periodically in the 
future.  The purpose and use of the updated analyses are for country decision-making and 
demand assessments and are not to be used for vaccine eligibility assessments, which will be 
based on the 2008 Pneumococcal GSP.  
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A. Vaccine 
serotypes 
The serotypes in the vaccine formulation must cover at least 60% of the 
invasive disease isolates in the target region, and must include 
serotypes 1, 5 and 14 which are the most frequent isolates in GAVI 
eligible countries. 
 
B.  Immunogenicity 
 
For pneumococcal conjugate vaccines, the main method of evaluation of immunogenicity is 
quantification of serum IgG using ELISA, although many studies have also used 
opsonophagocytic assays to evaluate functional antibody activity.  Analysis of data from the 
NCKP clinical trial suggested that a titre ≥0.20 μg/ml 1 month following receipt of the third 
dose of the primary series predicted protection against invasive disease (50).  A re-analysis 
using additional data from other clinical trials indicated that ≥0.35  μg/ml was a more 
appropriate cut off (51); this cut-off also corresponded to a threshold of opsonic antibody titre of 
1:8, and no significant differences were seen among the different vaccine serotypes.  
Defining correlates of protection for otitis media has been more difficult.  An analysis of the 
Finnish Otitis Media study identified an association between antibody concentration and risk of 
otitis media, but large differences were seen between serotypes; the predicted efficacy for type 
19F was negligible up to the highest geometric mean concentration tested, but 6B was found to 
be highly efficacious (>65%) at a geometric mean concentration of 0.5 μg/mL (24). 
Immunogenicity in high risk populations also needs to be considered where the vaccine is likely 
to be used in such children.  Children with HIV are at a substantially increased risk of invasive 
pneumococcal disease.  PCV7 is immunogenic in children with HIV and has demonstrable 
efficacy against invasive disease in these children (52;53).  Manufacturers of pneumococcal 
vaccines eligible for AMC support should provide evidence of the immunogenicity of the 
vaccine in HIV positive children where relevant. 
Persons with sickle cell disease and other hemoglobinopathies resulting in functional asplenia 
are also at high risk for serious infections with S. pneumoniae (54-57).  PCV7 induces 
significant increases in serum antibody concentration among infants with sickle cell disease that 
appear to be as high as those induced in healthy infants (58).  In older children, 2 doses of PCV7 
followed by a booster with 23-valent pneumococcal polysaccharide vaccine resulted in higher 
GMCs and OPA titers than 23-valent polysaccharide vaccine alone (54).  The reactogenicity of 
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with sickle cell disease who had a 3-dose primary series of PCV7 had somewhat stronger 
reactions to a booster with 23-valent polysaccharide vaccine than those who had a single dose at 
12 months (58).  Preliminary analysis of invasive disease trends among children <5 years of age 
with sickle cell disease in Atlanta found that rates declined 66% in the 2 years following PCV7 
licensure, suggesting that routine use of PCV7 provides protection among children with sickle 
cell disease (59).  
For the majority of pneumococcal serotypes, nasopharyngeal carriage precedes invasive disease.  
Thus, reduction of carriage is likely to be associated with a reduced incidence of disease.   
Clinical trials of pneumococcal conjugate vaccines demonstrated a reduction in nasopharyngeal 
carriage of vaccine serotypes (15;16;60-62).  As expected on the basis of these results, routine 
use of pneumococcal conjugate vaccine in the US has reduced carriage of vaccine serotypes 
among children, although the overall prevalence of pneumococcal carriage has remained 
unchanged (7;63-67).  There was some evidence that the timing of immunization is important.  
In Texas, investigators found that while the overall prevalence of pneumococcal carriage 
remained between 24-30% for the visits from 6 to 18 months, the proportion of vaccine-type 
pneumococci dropped between the 12- and 18-month visits, corresponding to the timing of the 
4th dose; at the same time, carriage of non-vaccine type pneumococci increased (63).  In 
Kentucky, researchers evaluating carriage during a time of vaccine shortage noted that carriage 
of vaccine serotypes decreased following the third and fourth doses and that children with 
prolonged intervals between the second and third doses (>3 months) and the third and fourth 
doses (>8 months) were more likely to carry vaccine-type strains than children with shorter 
intervals between doses (65).  Studies also indicate that carriage of vaccine-type pneumococci 
fell among adults following vaccination of children (67).  Attempts have also been made to 
define correlates of protection against pneumococcal carriage.  Dagan (68) and Millar (69) 
found that higher IgG concentrations led to a decreasing probability of having a newly-acquired 
strain.  This was statistically significant for serotypes 14, 19F, and 23F, but like with otitis 
media, differences were seen by serotype.  The ongoing PneumoCarr "Grand Challenges" 
Project will investigate these issues further, although currently no firm guidelines are available .   
While reduction of carriage is likely to be a desirable outcome following pneumococcal 
vaccination no firm guidelines exist yet for this endpoint as part of the licensing pathway.   
However, demonstration of reduced vaccine type carriage following vaccination would be 
highly desirable.  
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B. Immunogenicity  Immunogenicity should be demonstrated in accordance with 
WHO criteria, which are based on non-inferiority to a licensed 
pneumococcal vaccine as outlined in WHO Recommendations 
for the production and control of pneumococcal conjugate 
vaccines. (WHO Technical Report Series, No 927, 2005 and 
any subsequent published guidance). 
 
C. Target population/ Target age groups 
 
Pneumococcal disease rates are highest in children <5 years of age, are low in older children 
and healthy young adults, and increase again in the elderly (1;2).  Rates of disease and deaths 
are higher in developing countries than in industrialized settings.  In the US, which has among 
the highest reported invasive disease rates for industrialized countries, annual invasive disease 
incidence was 96/100,000 children <5 years before the pneumococcal conjugate vaccine was 
introduced (3).  In contrast, a recent study in Kenya estimated an incidence of presentation to 
hospital with pneumococcal bacteraemia of 597/100,000 children <5 years of age per year (4).  
Pneumococcal vaccines designed to have maximal public health impact must be optimised for 
disease prevention in children <5 years of age and in particularly be effective in those < 2 years 
of age.  
  
Attribute  Minimally acceptable profile 
C. Target 
population/ target 
age groups 
The vaccine must be designed to prevent disease among children 
<5 years of age and in particularly be effective in those < 2 years 
of age. 
 
D.  Safety, reactogenicity and contra-indications 
 
Clinical trials found PCV7 and PCV9 to be well-tolerated, and passive post-licensure 
surveillance for adverse events following receipt of PCV7 has indicated that the safety profile is 
comparable to other routinely used vaccines (70).  Fever rates in the NCKP trial were higher 
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fever, was higher among PCV9 recipients in The Gambia trial (23).  In The Gambia, 
significantly more outpatient visits were made within a week after dose 1 among those receiving 
PCV9, but this difference was not seen with later doses.  An increased risk for reactive airways 
disease or asthma may be a concern in children receiving PCV7.  Preliminary observations 
among infants at the NCKP found reactive airway disease to be approximately 20% more 
common among PCV7 recipients than among historical controls (71).  In the South African 
PCV9 efficacy trial, rates of viral pneumonias requiring hospitalization within the first week 
after vaccination and asthma-related diagnoses at any time following vaccination were 
somewhat higher among vaccine recipients (22).  The WHO Global Advisory Committee on 
Vaccine Safety (GACVS) recently reviewed the current evidence on the safety of PCV7 and 
other pneumococcal conjugate vaccines and found it reassuring (19).  Nevertheless, as with any 
new vaccine, it will be important to conduct surveillance for possible, rare unexpected effects 
after it is introduced in the target population.  
Among low birth weight infants (LBW) and premature newborns (PT), rates of fever and local 
events after PCV vaccination were found to be similar in frequency to normal weight and age 
newborns when adjusted for clustering among multiple doses per child.  When stratified for 
individual doses there was more redness and swelling among LBW infants and more swelling 
among PT infants after dose 3 (72).  Since developing countries have a high prevalence of 
malnutrition and LBW infants, studies in those populations will be desirable to ensure the 
safety profile of the candidate vaccines. 
Attribute  Minimally acceptable profile 
D. Safety, 
reactogenicity  and 
contra-indications 
The safety and reactogenicity profile should be comparable to, or 
better than that of  the currently licensed pneumococcal conjugate 
vaccine. Contra-indications should be restricted to known 
hypersensitivity to any of the vaccine components. 
 
E.  Vaccine dosage schedules 
 
Clinical trials of PCV7 conducted in the US used a schedule of 2, 4, 6, and 12 months of age 
(15;21) and a 4-dose series was subsequently licensed and recommended.  However, a growing 
body of evidence suggests that fewer than 4 doses may be effective.  Phase III trials of the 9-
valent vaccine in South Africa and The Gambia showed that a 3-dose primary series given in the 
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partially vaccinated children was 85.7% (95% CI 0, 100) (21).  In Italy, a single-blind cohort 
study of vaccination at 3, 5, and 12 months showed less radiologically confirmed pneumonia, 
acute otitis media, and antibiotic use in children who had received PCV7 compared to those 
who had not, but the effects were not statistically significant after 12 months of age (34). 
Shortages of PCV7 that occurred in the US between 2001 and 2004 provided an opportunity to 
evaluate the effectiveness of incomplete vaccination with pneumococcal conjugate vaccine.   
Combined data from two surveillance programs -the U.S. Pediatric Multicenter Pneumococcal 
Surveillance Group and the Massachusetts Department of Public Health – estimated that in 
children not at high risk for invasive disease, the effectiveness against vaccine serotypes was 
91% for the full 4-dose schedule, 77% for 3 doses given before 7 months of age, and 71% for 2 
doses given before 5 months of age (40).  A single dose given before 3 months of age did not 
provide statistically significant protection against vaccine serotypes, and none of the vaccine 
regimens provided significant protection against non-vaccine serotypes (41;41).  Examination of 
different schedules found that nearly all provided some protection compared to no vaccine, 
although a single dose at <7 months was less protective than 2 or 3 doses received at <7 months 
of age.  A direct comparison of 3 doses before 7 months of age plus a booster at 12-15 months 
with 3 doses before 7 months without a booster suggested that the booster added additional 
protection (p=0.03).  Immunogenicity evidence from several studies in industrialised countries 
shows that schedules with two doses <6 months of age followed by a booster dose around 12 
months, as expected, increases antibody levels above those elicited with a primary series.  (73-
76). Some serotypes like 6B and 23F may show lower antibody responses with less doses of 
vaccine, but this can be overcome by a booster.  More immunogenicity data will be forthcoming 
on reduced dose schedules. 
There are differences in responses to conjugate vaccines between developed and developing 
country settings.  For example, an evaluation of PCV9 immunogenicity in the UK found that 
antibody levels increased following either 2 or 3 infant doses but declined to near pre-vaccine 
levels before the booster dose was given at 12 months (75).  In contrast, in South Africa among 
HIV-uninfected children, antibody levels remained higher than among controls for up to 5 years 
(53).  While direct comparisons between exact IgG GMC values from studies done at different 
times or in different laboratories should be undertaken with caution, antibody levels 4 weeks 
after the 3
rd infant dose in African studies (16;77) were generally higher than that seen after the 
3
rd infant dose in the UK PCV9 study (75) or in PCV7 studies in the US (21;78).  The reasons 
for these differences are poorly understood but may relate to the degree of natural exposure to 
vaccine-type and cross-reactive organisms and/or the maturation of immune responses.  Further 
information will be available when data from reduced infant dose studies in Kenya 
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vaccination using surveillance and immunogenicity data suggested that a single dose of 
conjugate vaccine could be effective if the timing of administration is chosen carefully (79).  
Although a single dose was not predicted to be as effective as a 3- or 4-dose regimen, the model 
suggested that a single dose given between 5 and 7 months of age could prevent up to one-third 
of invasive pneumococcal disease. 
Given these considerations, the target pneumococcal conjugate vaccine candidates for 
developing countries should be designed to elicit appropriate antibody responses using a 
maximum of 3 doses in infancy.  The current developing country dose schedules vary among 
the regions, Latin America uses a 2, 4 and 6 month schedule, while Africa and Asia use the 
WHO recommended schedule of 6, 10 and 14 weeks.  At a minimum, the vaccine should 
perform well when administered according to both of these schedules and the first dose should 
ideally be given at 6 weeks of age or earlier.  The possibility of alternative schedules (e.g. two 
or less infant doses and a later dose at 9-12 months) should also be explored.  WHO is currently 
undergoing a careful review of the EPI recommended schedule to adjust it to the newly 
available and future public health vaccines.    
Data on duration of protection for pneumococcal vaccines are somewhat limited.  WHO has 
proposed a concentration of IgG anticapsular polysaccharide antibodies by ELISA of > 
0.35μg/ml as protective, derived from the pooled estimate of data from 3 studies conducted in 
North America and Africa.  However, as compared to Hib protective levels, no specific 
threshold has been defined for long term protection against pneumococcal disease.  Priming for 
subsequent memory responses in the absence of persisting anti-capsular antibody may not be 
enough, as the incubation of S. pneumoniae infections is short and antibody levels are 
paramount for the protection of disease as demonstrated recently in the UK with Hib infections.  
However, in South Africa, HIV-uninfected children who received 3 infant doses of PCV9 
showed no reduction in efficacy for up to 6 years, and antibody levels remained higher than 
among controls for up to 5 years (53); protection and antibody levels waned in HIV-infected 
children.  Provided that 3 doses of vaccine in the first year of life will be efficacious in 
developing countries, information on the need for booster doses may be desirable in the 
future to answer questions on herd immunity effects and persistence of protection. 
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E. Dosage schedule  Vaccine scheduling must be compatible with national infant 
immunization programmes and consist of not more than 3 doses 
in the first year of life.  The first dose must be shown to be 
administrable at 6 weeks of life or earlier. 
 
F.  Interference and co-administration with other vaccines 
 
Co-administration of PCV7 with DTwP or DTaP, Hib, hepatitis B, and OPV or IPV is not 
associated with a clinically significant reduction in the response to any of the vaccines.   
Variable responses, especially lower GMC to pertussis antigens, have been demonstrated in a 
few studies when DTaP is co-administered with PCV-7 (80-82).  However, these studies varied 
in schedule intervals and antigens delivered.  In a study of PCV7 plus DTP-IPV/Hib, 96-100% 
of children achieved a post-dose three with IgG concentration of >0.15 μg/ml (the threshold 
chosen for this study) against each of the seven pneumococcal serotypes, showing no 
interference.  Local reactions were significantly less frequent at the PCV7 injection site than at 
the DTP-IPV/Hib injection site; with the exception of fever >38 °C, systemic reactions were 
comparable (81). 
The target candidate pneumococcal vaccines should provide evidence of no clinically 
significant immunological interference and safety interaction with vaccines administered 
concurrently in infancy as part of the national immunization programs in developing countries.   
Attribute  Minimally acceptable profile 
F. Interference and 
co-administration 
with other vaccines 
There should be no clinically significant interaction or interference 
in relation to safety and immunogenicity with concurrently 
administered vaccines. 
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The intramuscular (IM) route is the only route of administration currently recommended for 
administration of pneumococcal conjugate vaccines in children.  However, some data on 
subcutaneous (SC) administration are available for the 23-valent polysaccharide vaccine in 
adults.  In a randomised, observer blind study of 254 elderly subjects, the immunogenicity of a 
23-valent pneumococcal vaccine was not influenced by its route of administration (83).  A low 
rate of systemic adverse reactions was observed with the vaccine (SC and IM both 6.3%).  Local 
adverse reaction rates were: IM 7.1% and SC 18.9%, suggesting IM is a safer route, but in 
adults this response is influenced by previous levels of anti-pneumococcal antibodies (83).   
Theoretically, intra/trans-dermal, intranasal, aerosol vaccine administration or other routes may 
have advantages, both in terms of dose, immunogenicity and ease of administration for large-
scale use.  Vaccine developers are encouraged to explore these routes of administration. 
 Attribute  Minimally acceptable profile 
G. Route of administration  Intramuscular or subcutaneous.  
 
H. Product presentation 
 
Vaccine packaging and presentation needs to be adapted to the programmatic requirements in 
developing countries.  Inappropriate packaging and vial sizes can add substantially to the cost of 
immunization through excessive storage requirements, product wastage and others.  The 
consideration of wastage is particularly important for vaccines that cost more than traditional 
EPI vaccines.  A group of experts, the Vaccine Packaging and Presentation Advisory Group 
(VPPAG, see acknowledgements), has investigated several options of product presentation for 
pneumococcal vaccine, based on the likely price range for this vaccine and applying real 
wastage rates.  
Based on this analysis the best presentation options are mono-dose and low multi-dose vials.  
Mono-dose presentations, in particular if available as auto-disable compact prefilled devices, 
help to assure safety of injection, reduce work load to health care workers, and reduce wastage 
of vaccines.  Low multi-dose vials have reduced storage requirements and acceptable wastage 
rates. Preliminary analysis suggests that vials containing between 2-5 doses are appropriate. 
However, the selection of the number of doses per vial should be defined by the manufacturer.    
  Page  25  18/12/2008 To allow for use through subsequent immunization sessions, the vaccine needs to contain 
preservative at appropriate concentration as outlined in the Global Advisory Committee of 
Vaccine Safety statement (http://www.who.int/vaccine_safety/topics/thiomersal/en/index.html; 
accessed 18.10.2007).  If a low multi-dose vaccine contains no preservative, it needs to be 
discarded at the end of the immunization session, and at latest 6 hours after the vial has been 
opened.  To distinguish such products from those containing preservative, a specific labeling of 
the vial will be required.  WHO is currently revising its policy on the use of opened multi-dose 
vials (The use of opened multi-dose vials of vaccine in subsequent immunization sessions, 
WHO/V&B/00.09), and information on the labeling should be obtained from WHO. 
In conclusion, for the TPP, mono-dose or low multi-dose vial presentations are considered 
essential..  For mono-dose presentations, either single dose vials or auto-disable compact pre-
filled devices must be used.  All presentations should be optimized for space-efficiency in 
accordance with the WHO Guidelines on the international packaging and shipping of vaccines 
(WHO/IVB/05.23).   
 Attribute  Minimally acceptable profile 
H. Product 
presentation  
The vaccine must be available in mono-dose or low multi-dose presentations. 
Mono-doses must be either a single dose vial or a auto-disable compact pre-
filled device. Low multi-dose presentations must be formulated and labelled in 
compliance with WHO policy or guidance. 
 
I.  Product formulation 
 
Lyophilized vaccine formulations may have advantages in relation to storage temperature but 
the disadvantages for field use are several, including the need for reconstitution, additional 
storage capacity for the diluent, greater workload, especially when vials contain small number 
of doses, which will be the case for pneumococcal vaccines.  It is therefore recommended that 
only liquid formulations will be used.  The target volume should be 0.5ml/dose.  This volume 
represents a balance between ease of administration and minimal pain on injection, and is the 
most frequently used in immunization. 
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I. Product formulation  Liquid formulation with a standard volume of 0.5 ml/dose 
 
J.  Storage and cold chain requirements 
 
Available pneumococcal vaccines and those in advanced development are all liquid 
formulations requiring storage at 2 to 8 °C.  Liquid vaccines containing aluminium adjuvants 
should not be frozen.  If freeze-sensitive, pneumococcal vaccine manufactures should allow the 
use of the ‘shake test’ or other means (such as a vial-based freeze indicator) to assess whether 
freeze damage has occurred.  Vaccine shelf life should be in accordance with WHO 
requirements (24 months), but a prolonged shelf life would be desirable.  Vaccine vial 
monitors (VVM) to measure exposure to high temperature should be attached in accordance 
with existing WHO policy as outlined in Making use of vaccine vial monitors.  Flexible vaccine 
management for polio (WHO/V&B/00.14).  Vaccines with increased  thermostability are 
desirable because they permit more flexible use of the vaccine and ideally, new vaccines 
would not need a cold chain. 
Attribute  Minimally acceptable profile 
J. Storage and cold 
chain requirements 
The product must be stable at 2-8 °C with a shelf-life of at least 
24 months and a vaccine vial monitor should be attached as 
outlined in Making use of vaccine vial monitors. Flexible vaccine 
management for polio (WHO/V&B/00.14). 
 
K.  Vaccine packaging and labelling 
 
The vaccine should be packaged and boxed in a format designed to fit the widest range of 
currently deployed cold chain equipment.  Extensive guidance is available from WHO 
Guidelines on the international packaging and shipping of vaccines (WHO/IVB/05.23).   
Equally, product name and labelling should follow internationally accepted standards set out in 
Recommendations for the production and control of pneumococcal conjugate vaccines. (WHO 
Technical Report Series, No 927, 2005). 
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K. Packaging and 
labelling 
Name and labelling must be in accordance with WHO 
Recommendations for the production and control of pneumococcal 
conjugate vaccines. (WHO Technical Report Series, No 927, 
2005).  Packaging must ensure minimal storage space requirements 
as set out in Guidelines on the international packaging and 
shipping of vaccines (WHO/IVB/05.23). 
 
L.  Product registration and prequalification 
 
Each vaccine procured via the AMC will require WHO prequalification as outlined in the 
Procedures for assessing the acceptability, in principle, of vaccines for purchase by United 
Nations agencies (WHO/IVB/05.19). In addition, WHO has developed guidelines on how to 
expedite country-level registration of a pre-qualified vaccine (see Procedure for expedited 
review of imported prequalified vaccines for use in national immunization programmes 
(WHO/IVB/07.08)). 
Attribute  Minimally acceptable profile 
L. Product 
registration and 
prequalification 
The product must be WHO pre-qualified in accordance with 
Procedures for assessing the acceptability, in principle, of 
vaccines for purchase by United Nations agencies 
(WHO/IVB/05.19). 
 
M.  Post marketing surveillance 
 
All newly introduced vaccines should be monitored through post marketing surveillance.  Of 
particular interest are the monitoring of safety, protection of the target population, indirect 
effects (herd immunity) and potential serotype replacement following widespread use of the 
vaccine. 
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M. Post Marketing 
Surveillance 
Post-marketing surveillance should be conducted in accordance with 
national regulatory authorities and WHO prequalification 
requirements as set out in Guideline for preparation of the product 
summary file for vaccine prequalification (WHO/IVB/06.16) , 
Guidelines on clinical evaluation of vaccines: regulatory 
expectations (WHO Technical Report Series, No 924, 2004) and any 
relevant published guidance.  
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